Articles tagged with Pancreatic Cancer
A new study finds that high fasting glucose has surpassed tobacco use as the leading risk factor for pancreatic cancer in the US, while China faces a dual metabolic-tobacco burden. China recorded more absolute cases, but lower age-standardized rates, with a peak burden at ages 60-74.
Researchers have identified three subclusters of cells driving pancreatic cancer-induced cachexia, a muscle-wasting and fat-loss condition that affects pancreatic cancer patients. The subclusters form a triangular regulatory network that drives the initiation and progression of cachexia.
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
A regulator-mandated study found no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden, and Norway. The study, funded by Novo, included over 97,000 semaglutide users and compared them to users of other non-incretin antidiabetic drugs.
A randomized phase 2 trial found that five treatments of stereotactic body radiation therapy (SBRT) better preserved physical function and reduced fatigue compared to 28 treatments of conventional radiation therapy with chemotherapy. Rates of cancer remaining in lymph nodes did not differ significantly between the groups.
Researchers developed an AI model that accurately predicted pancreatic cancer risk three years before diagnosis, using a patient's comprehensive health history and routine laboratory tests. The model achieved high accuracy in distinguishing between at-risk and low-risk individuals, with an AUROC of 0.853.
A Chinese registry report presents real-world perioperative and survival outcomes for surgically treated pancreatic cancer patients, achieving high overall survival rates and encouraging surgical safety metrics. The study emphasizes the need for national-level benchmarks and standardized clinical protocols for pancreatic surgery in China.
A new, incisionless liver cancer treatment called histotripsy was associated with low rates of laboratory toxicity and procedural complications in a real-world review of 972 patients. However, the study found that 11% of patients died within 30 days, suggesting that advanced cancer and overall disease burden may be contributing factors.
Daraxonrasib, a novel RAS-targeted therapy, has been approved for adults with metastatic pancreatic adenocarcinoma. Clinical trials have shown a median overall survival of 13.2 months and nearly three times the objective response rate compared to chemotherapy. The medication targets KRAS, NRAS, and HRAS mutations, covering over 90% of ...
A new blood test, PANXEON, detects stage 1 and 2 pancreatic cancer with high sensitivity and low false-positive rates, identifying high-grade dysplasia with 64% accuracy. The test could enable early intervention and improve treatment options for patients with inherited risk or family history of pancreatic cancer.
Researchers found that spatial patterns in pathology slides can identify patients at greater risk of pancreatic cancer recurrence after treatment. AI-enabled analysis measured tissue shape, fragmentation, and cancer-stroma intermixing to predict disease-free survival.
Researchers found that pancreatic cancer cells create localized immune-protective niches that shield tumors from immune attack. Disrupting these protective mechanisms slowed tumor growth and improved responses to immunotherapy in preclinical models.
Massey researchers will evaluate TROP2 targeted ADCs for breast and pancreatic cancer care, aiming to identify predictive biomarkers and therapeutic strategies. The grant will help develop a test to predict patient drug response and identify secondary treatments for resistant tumors.
A new device uses electricity to separate cancer-associated signals from healthy particles in the blood, offering a new method for studying pancreatic cancer. The device, which sorts particles based on their electrical charge, showed promise in distinguishing cancer samples from healthy ones.
Daraxonrasib, the first approved RAS-targeted therapy, nearly doubles median overall survival in metastatic pancreatic cancer patients, with a 60% reduced risk of death. The phase 3 RASolute 302 trial showed substantial improvement in overall survival and cancer progression compared to chemotherapy.
Researchers have developed an mRNA immunotherapy that eliminates pancreatic tumors in mice, achieving complete tumor responses and long-term disease-free periods. The treatment uses a cocktail of immune cytokine and tumor-associated antigen mRNAs, showing promise as a potential transformative treatment for pancreatic cancer.
Researchers at Purdue University have developed L-32, a quinolone-based inhibitor that targets PTPN22, a negative regulator of the immune system. This compound promotes robust antitumor immunity and has improved potency, selectivity, and cellular efficacy compared to previous derivatives.
Researchers estimated cancer risk in patients with pancreatic cysts with worrisome or high-risk features, finding that risk increased with the number of worrisome features. The study suggests that regular surveillance may be an appropriate approach for some patients rather than immediate surgery.
Researchers identify AGR2 as a prognostic marker for NF-PanNETs, while FOXM1 is found to promote malignancy and proliferation. AGR2-high cells exhibit malignant features, including increased proliferative activity and metastasis-like signatures.
The updated guideline provides evidence-based recommendations on radiation therapy for adult patients with pancreatic cancer, clarifying its role in various settings. It recommends radiation therapy for patients with resectable, locally advanced, and metastatic disease, as well as those with recurrent or palliative needs.
Researchers developed a new approach called SHIFTERS that uses focused ultrasound to temporarily 'light up' solid tumors, giving cancer-fighting immune cells a target they can recognize. The technology allows doctors to control where and when treatment switches on, potentially making solid tumors easier to treat.
Scientists at Cancer Research UK Scotland Institute and University of Glasgow identify a new pathway for delivering antisense oligonucleotides (ASOs) into cells, enhancing the effectiveness of ASO-based therapy for pancreatic cancer and other diseases. The researchers found that ASOs enter cells via endocytosis and bind to specific rec...
Researchers at USC have developed a genetic tool called the Mechano-Recorder to measure tumor cell softness. This insight can help target hard-to-reach cancer stem-like cells for destruction, potentially improving cancer treatment outcomes.
A Rutgers Cancer Institute physician-scientist says a VA study comparing two hormone therapies for metastatic prostate cancer provides strong real-world evidence to help doctors choose the right drug for each patient. The study found that enzalutamide may offer a modest survival advantage for patients aged 75 and older.
A University of Oklahoma researcher is receiving a five-year, $2 million NCI grant to investigate how pancreatic cancer uses cholesterol to survive chemotherapy. The research aims to identify new ways to treat this deadliest form of cancer by uncovering the biological processes that help tumors thrive.
A NIH-funded research project has generated a comprehensive collection of patient-derived tumor models, covering 25 types of cancer from thousands of donor tissues. These models closely match their parental tumors in terms of genetic alterations and gene expression signatures, enabling researchers to explore tumor evolution and diversity.
Researchers developed an experimental drug using AI to target a 'undruggable' protein in pancreatic cancer, slowing tumor growth and improving survival rates. The study demonstrates the potential for AI-assisted discovery of new cancer treatments.
Researchers at the University of Chicago report a promising new strategy using BifidoSumIL-2, an engineered bacterial strain, to deliver an immune-stimulating therapy directly into pancreatic tumors. The treatment selectively activates cancer-fighting T cells and slows tumor growth, even when combined with chemotherapy or radiotherapy.
University of Minnesota researchers found that certain immune cells, regulatory T cells, prevent helpful T cells from eliminating hidden cancer cells. By combining treatment strategies, they improved the immune response and reduced cancer spread in preclinical models.
The IRP1/ARID3A complex suppresses ferroptosis and promotes chemoresistance in pancreatic cancer by epigenetically silencing cytoglobin (CYGB). Restoration of CYGB expression reverses these effects, sensitizing tumor cells to ferroptosis and improving treatment outcomes.
A vaccine targeting KRAS mutations was safe and stimulated durable immune responses in high-risk individuals. After a median follow-up of 16.5 months, none of the participants developed pancreatic cancer, and some precancerous lesions shrank or stopped growing.
Sylvester researchers develop AI-powered fracture prediction models, train as wildland firefighters to reduce cancer risk, and discover new targets for pancreatic cancer treatment. A new tumor-on-a-chip model shows how pancreatic cancer hijacks immune cells.
Researchers developed nanoparticles that retain their protective coating in normal tissue but shed it upon reaching tumor tissue, releasing anticancer drugs. This technology reduces systemic side effects and enhances treatment efficacy.
A new preclinical study has identified a gut bacterium, Akkermansia muciniphila, that helps prime intestinal stem cells for faster recovery after radiation treatment. Fasting increases the population of this bacterium, which produces a small molecule that changes histone tags to allow gene expression in intestinal cells.
Researchers have developed a microfluidic platform that recreates the complex ecosystem surrounding pancreatic tumors and observed how cells interact dynamically. The findings reveal a critical mechanism that may explain why many therapies fail and point to new therapeutic strategies.
A Phase I/II study showed high tumor shrinkage and substantial reductions in cancer DNA detected in the bloodstream. The treatment combination of zoldonrasib with chemotherapy improved patient outcomes, suggesting a potential breakthrough in personalized treatment for pancreatic cancer.
Researchers have uncovered a potential strategy to eliminate cancer cells that survive KRAS inhibition, preventing relapse. By targeting the metabolic pathways that support the survival of drug-tolerant persister cells, treatment regimens could be designed to shrink tumors and prevent cancer recurrence.
A multidisciplinary panel of experts recommends evidence-based screening and surveillance strategies for pancreatic cancer in high-risk populations, aiming to improve early diagnosis and survival. The guidelines specify starting ages, surveillance intervals, imaging modalities, surgical indications, and lifestyle modifications.
Pre-retrieval imaging is revolutionizing liver transplantation by improving graft selection, reducing uncertainty, and supporting better surgical planning. Imaging modalities like ultrasound, CT, and MRI offer distinct strengths and limitations in evaluating liver graft quality, vascular anatomy, and biliary variants.
Researchers have identified IL1RAP as a key player in the tumor-driven inflammatory network that helps pancreatic cancer resist treatment. Blocking this receptor may help break down tumors and improve response to combination therapy.
Researchers at Salk Institute uncover an unexpected role for HDAC enzymes in controlling critical genes involved in DNA repair, making pancreatic cells more vulnerable to therapies that induce DNA damage. This finding paves the way for new treatment strategies combining entinostat with DNA-damaging therapies.
A team of researchers has identified a previously unknown vulnerability in KRAS-mutated pancreatic cancer cells, making them susceptible to necroptosis. Blocking the tumor cells' defense mechanism by inhibiting caspase-8 leads to significant cell death and reduced tumor growth.
Scientists at VUB mapped healthy pancreas cells down to the cellular level, discovering rare cells with properties similar to aggressive tumour cells. This fundamental discovery may offer opportunities for early detection of pancreatic cancer, currently one of the most difficult diseases to treat.
Researchers investigated polyisoprenylated cysteinyl amide inhibitors (PCAIs) for their anticancer effects on pancreatic cancer cells with KRAS mutations. The compounds demonstrated strong activity against cell survival, migration, and invasion pathways. PCAI treatment caused hyperactivation of MAPK and PI3K/AKT pathways, leading to ox...
A study of over 229,000 obese adults without diabetes found that weight loss drugs, such as semaglutide and tirzepatide, were associated with a 41% decrease in the overall risk of developing obesity-related cancers. GLP-1 RAs also showed larger reductions in certain subgroups, including men and gynaecologic cancers.
The AGA GI Opportunity Fund invests in Amplified Sciences to advance PanCystPro, a next-generation diagnostic assay for improving pancreatic cyst risk assessment. The funding supports completion of a pivotal real-world observational study and expansion of commercial partnerships.
Researchers at UMass Amherst have designed a new therapy that combines engineered Salmonella bacteria with oncolytic viruses to target liver and pancreatic cancer. The treatment showed promising results in animal models, leading to significant tumor reduction and improved survival rates.
Researchers at IRB Barcelona used AI to design new chemical entities that selectively target specific cell types, demonstrating superior activity compared to conventional screening strategies. The methodology, called phenotypic discovery, uses observable responses in cells rather than a specific molecular target.
The study found high-risk associations between alcohol use and all ten cancers examined, with risk increasing progressively as intake rose. Low-to-moderate drinking was associated with lower disease risk for type 2 diabetes, Alzheimer's disease, ischemic heart disease, and stroke.
Researchers highlight latest developments in pathology, diagnosis, and treatment of MASLD and IPFD, revealing correlations with chronic diseases like liver cancer and pancreatic cancer. Innovative treatments, such as AI-driven approaches and organ-targeted therapies, show promise for precision prevention and therapy.
A study published in the New England Journal of Medicine shows an investigational targeted therapy, daraxonrasib, significantly extends overall survival for patients with metastatic pancreatic cancer, reducing death risk by 60%, compared to standard chemotherapy.
A phase 3 trial shows daraxonrasib, an oral RAS(ON) multi-selective inhibitor, improves overall and progression-free survival compared to chemotherapy in patients with metastatic pancreatic cancer. The treatment also demonstrated substantial tumor shrinkage or disappearance in patients with a known RAS G12 mutation.
Researchers found that a vitamin D analog reduced fibroblast activation and increased T cell infiltration in pancreatic tumors, improving chemotherapy responses and progression-free survival. Patients with high vitamin D receptor expression also had longer overall survival.
Researchers at Memorial Sloan Kettering Cancer Center have uncovered promising combination therapies for a rare childhood brain tumor by analyzing patient samples, cell models, and laboratory data. The study found that cancer cells can develop workarounds to evade targeted RAS therapies, highlighting the need for new treatment strategies.
Researchers will present multiple studies with practice-changing results in various cancers, including pancreatic, prostate, breast, and multiple myeloma. The findings include new treatment strategies and the potential impact of lifestyle factors.
A lower CA19-9 cutoff of 7 units/mL can identify patients with pancreatic cancer who have high-risk disease despite low biomarker levels. This dual-threshold model helps distinguish between true low tumor burden and Lewis antigen-negative status, improving prognostic assessment.
Researchers have discovered that precursor lesions in the pancreas, often considered a step towards cancer, do not undergo malignant transformation if they lack a specific microenvironment. The team used advanced technologies to isolate and analyze single cells from over 150 donated pancreases, finding that the microenvironment surroun...
A new study published in JAMA Network Open found that patients with low-risk pancreatic cystic lesions have a high risk of developing pancreatic cancer. The study highlights the need for long-term personalized surveillance strategies for these patients, which could enable earlier detection and treatment of the disease.
Researchers have developed a targeted radiopharmaceutical treatment that can effectively slow tumor growth in pancreatic ductal adenocarcinoma, achieving complete remission in preclinical models. The treatment targets CD44v6 expression and has shown promise as a new option for patients with this highly aggressive cancer.
A new study reveals that the cancer-causing protein MYC plays a direct role in fixing damaged DNA in tumor cells. This allows cancer cells to survive chemotherapy and other treatments, contributing to tumor resistance and poor patient outcomes. The findings could lead to new therapies targeting MYC's repair function.